[Ip-health] UACT STATEMENT REGARDING COMPULSORY LICENSE ON REVLIMID IN RUSSIA

Manon Ress manon.ress at cancerunion.org
Mon Jul 16 11:13:08 PDT 2018


UACT STATEMENT REGARDING COMPULSORY LICENSE ON REVLIMID IN RUSSIA

JULY 16, 2018

http://cancerunion.org/2018/07/16/uact-statement-regarding-compulsory-license-on-revlimid-in-russia/

UACT Statement Regarding Compulsory License on Revlimid in Russia
The Union for Affordable Cancer Treatment (UACT) welcomes the news that a
Russian court has approved a compulsory license for patents held by Celgene
for the cancer drug lenalidomide, marketed in many countries under the
trade name Revlimid. Compulsory licenses on patents can promote health and
protect the interests of cancer patients when there is excessive pricing
and other abuses of a legal monopoly.

Since entering the market, Revlimid has generated more than $46 billion in
sales for Celgene, including $2.3 billion in the first three months of
2018. In the United States, Celgene still claims the drug is protected by
26 patented inventions and the company has also been cited by the Federal
Trade Commision for anti-competitive actions to block entry by generic
suppliers.

UACT and its members are hoping many other countries will follow suit and
make this drug available at a better price for the many patients who need
it today.

In the United States, the executive branch and members of Congress are
considering legislation to mandate or authorize negotiations for drug
prices in the U.S. Medicare program. As UACT has previously stated, having
robust authority to grant a compulsory license on drug practices and other
exclusive rights are necessary to ensure that patient access is protected
in such negotiations. Revlimid is used to treat patients of all ages, many
of whom would not be insured by Medicare in the US. This case highlights
why proposals for a national compulsory licensing authority should not be
limited to a single government program or a subset of the population.

Concerned that the prices of essential cancer drugs are continuing to
increase, UACT and its members support the use of existing mechanisms such
as compulsory licensing to provide more access to more patients.

Contact: Manon Ress

Email: manon.ress at cancerunion.org


-- 
Manon Ress, Ph.D.
Union for Affordable Cancer Treatment (UACT)
Cell Phone +1 571 331 6879
www.cancerunion.org
Email: info at uact.org
Twitter: @Cancer_Union
Telephone: 202.332.2670

Mailing Address:
1621 Connecticut Avenue NW
Suite 550
Washington, DC 20009


More information about the Ip-health mailing list